AI clinical trials in India could lower drug-development costs, but CDSCO's framework must evolve as virtual trial simulations gain traction.
Anupam Rasayan moves beyond agrochemicals into branded pharma CDMO after acquiring Bliss GVS Pharma for Rs 1,750 crore.
Paediatric GLP-1 drugs in India face closer scrutiny after WHO prioritised lifestyle interventions and called for stronger evidence before wider use in children.
Neuberg and NM Medical’s merger strengthens Maharashtra’s preventive healthcare network, combining advanced diagnostics, imaging and wellness services with a Rs 500 crore revenue target.
Complex injectables in Indian pharma are gaining importance as companies invest in specialised R&D, complex formulations, and higher-value drug development.
India’s biopharma leap is gaining momentum as peptides and ADCs drive investment, advanced therapeutics, precision diagnostics and manufacturing growth.
Glenmark adapalene 0.1 percent launch in the US highlights an established acne therapy and its relevance to India's evolving dermatology treatment landscape.
Zydus advances its specialty ambitions with the first generic Adempas launch in the U.S., expanding access to lower-cost pulmonary hypertension treatment.
Epcoritamab DLBCL treatment gains momentum as AbbVie and Genmab report a 51 percent reduction in progression or death risk.
Serum Institute’s WHO nod for Cervavac strengthens India’s cancer-free vision by expanding access to an indigenous HPV vaccine.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
